Assenagon Asset Management S.A. Affimed N.V. Transaction History

Assenagon Asset Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 01, 2021	SELL	$3.16 - $7.03 $427,352 - $950,723	-135,238 Closed	0 $0
Q3 2020 Oct 07, 2020	SELL	$3.26 - $4.73 $998,114 - $1.45 Million	-306,170 Reduced 69.36%	135,238 $458,000
Q2 2020 Jul 21, 2020	BUY	$1.58 - $4.63 $697,424 - $2.04 Million	441,408 New	441,408 $2.04 Million
Q3 2019 Oct 16, 2019	SELL	$2.67 - $3.65 $506,442 - $692,328	-189,679 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$2.6 - $4.21 $493,165 - $798,548	189,679 New	189,679 $544,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.